miRNA-122与丙肝病毒感染及肝癌关系的研究进展  

Studies About the Relationship between miR-122 and Hepatitis C Virus and Hepatocellular Carcinoma

作　　者：王方平[1] 张平安[1] 牛志立[1] 

机构地区：[1]武汉大学人民医院检验科

出　　处：《现代检验医学杂志》2016年第5期157-159,164,共4页Journal of Modern Laboratory Medicine

摘　　要：丙型肝炎病毒（hepatitis C virus，HCV）感染机体后易发展为肝炎、肝硬化及肝癌。目前，传统治疗方法为聚乙二醇干扰素联合利巴韦林，其效果不佳且副作用大，而新型直接抗病毒药物价格昂贵。因此，寻求廉价而无毒副作用的抗 HCV感染治疗方法是目前研究的重点。越来越多的证据表明，微小核糖核酸（micro-ribose nucleic acid，miRNAs）在肝脏疾病发展、肝细胞再生和功能调节等方面发挥着重要的作用。该文就miR-122与丙肝病毒感染及肝癌关系的研究现状作一综述。Hepatitis C virus （HCV）was easily developed into hepatitis,cirrhosis and liver cancer after infecting human.Cur-rently,the traditional method of treatment of HCV was pegylated interferon and ribavirin program,which was ineffective and had poor side effects,while the new direct antiviral drugs were expensive.Therefore,looking for cheap and non-toxic side effects of treatment was the focus of current research.More and more evidence indicate that micro-Ribose Nucleic Acid （miRNAs）play an important role in the development of liver disease,regeneration and functional regulation.This review studies the relationship between miR-122 and Hepatitis C virus and hepatocellular carcinoma.

关 键 词：微小RNA-122 丙肝病毒 肝癌 

分 类 号：R512.63[医药卫生—内科学] R735.7[医药卫生—临床医学]